| Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice. | |
| | |
MedLine Citation:
|
PMID: 18671992 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Type 1 diabetes is an autoimmune disease characterized by inflammation of pancreatic islets and destruction of beta cells by the immune system. Opioids have been shown to modulate a number of immune functions, including T helper 1 (Th1) and T helper 2 (Th2) cytokines. The immunosuppressive effect of long-term administration of opioids has been demonstrated both in animal models and humans. The aim of this study was to determine the effect of methadone, a mu-opioid receptor agonist, on type 1 diabetes. Administration of multiple low doses of streptozotocin (STZ) (MLDS) (40 mg/kg intraperitoneally for 5 consecutive days) to mice resulted in autoimmune diabetes. Mice were treated with methadone (10 mg/kg/day subcutaneously) for 24 days. Blood glucose, insulin and pancreatic cytokine levels were measured. Chronic methadone treatment significantly reduced hyperglycemia and incidence of diabetes, and restored pancreatic insulin secretion in the MLDS model. The protective effect of methadone can be overcome by pretreatment with naltrexone, an opioid receptor antagonist. Also, methadone treatment decreased the proinflammatory Th1 cytokines [interleukin (IL)-1beta, tumor necrosis factor-alpha and interferon-gamma] and increased anti-inflammatory Th2 cytokines (IL-4 and IL-10). Histopathological observations indicated that STZ-mediated destruction of beta cells was attenuated by methadone treatment. It seems that methadone as an opioid agonist may have a protective effect against destruction of beta cells and insulitis in the MLDS model of type 1 diabetes. |
| | |
Authors:
|
K Amirshahrokhi; A R Dehpour; J Hadjati; M Sotoudeh; M Ghazi-Khansari |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-07-11 |
Journal Detail:
|
Title: Toxicology and applied pharmacology Volume: 232 ISSN: 1096-0333 ISO Abbreviation: Toxicol. Appl. Pharmacol. Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-22 Completed Date: 2008-10-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0416575 Medline TA: Toxicol Appl Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 119-24 Citation Subset: IM |
Affiliation:
|
Department of Pharmacology School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood Glucose / drug effects Cytokines / metabolism Diabetes Mellitus, Experimental / drug therapy*, immunology, metabolism Diabetes Mellitus, Type 1 / chemically induced, drug therapy*, immunology, metabolism Drug Administration Schedule Hypoglycemic Agents / pharmacology* Immunosuppressive Agents / pharmacology* Injections, Intraperitoneal Insulin / blood Methadone / pharmacology* Mice Naltrexone / pharmacology Narcotic Antagonists / pharmacology Pancreas / drug effects*, immunology, metabolism, pathology Receptors, Opioid, mu / agonists*, metabolism Streptozocin / administration & dosage Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Cytokines; 0/Hypoglycemic Agents; 0/Immunosuppressive Agents; 0/Narcotic Antagonists; 0/Receptors, Opioid, mu; 11061-68-0/Insulin; 16590-41-3/Naltrexone; 18883-66-4/Streptozocin; 76-99-3/Methadone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Post-hatch oral estrogen exposure reduces oviduct and egg mass and alters nest-building behavior in ...
Next Document: Evidence against the nuclear in situ binding of arsenicals--oxidative stress theory of arsenic carci...